Design and Characterization of Oral Mucoadhesive Buccal Films of Empagliflozin

An anti-diabetic drug called Empagliflozin is used to control blood glucose levels in type 2 diabetics. Due to the high rate of hepatic first pass metabolism, it exhibits limited bioavailability. The current study was done to create Mucoadhesive buccal films of Empagliflozin with the aim of increasing bioavailability, patient compliance, and therapeutic efficacy. The solvent casting process used for the preparation of Empagliflozin Mucoadhesive buccal films by using the Mucoadhesive polymers like HPMC K100 and HEC. The prepared films' evaluated for weight variation, thickness, surface pH, uniformity of the drug content, in-vitro residence time, folding durability, in-vitro release, and permeation investigations were all assessed. Formulations (F1-F4) were created by altering the concentrations of various polymers, with F2 and F4 formulations having the highest polymer ratios and the longest-lasting drug release rates. According to characterization results such as in-vitro dissolution experiments, the sustained release formulation F2, F4 shows the best drug release rate, the order of drug release is F1>F3>F2>F4. It was determined that the films could be chosen for the development of buccal films for effective therapeutic applications because they exhibited effective enlargement, a practicable residence duration, and promising controlled drug release.